Clinical Trial Update: Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of concomitant MMR rHA and VARIVAX given intramuscularly versus subcutaneously.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Measles
• Mumps
• Varicella

Drugs mentioned

• MMR (measles-mumps-rubella vaccine)
• Varivax (varicella vaccine (live attenuated))

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Measles, Mumps | Phase 3 | Status: COMPLETED